Using pharmacoepidemiology to optimize antihypertensive medication use to prevent aging-related multimorbidity: Midcareer investigator award in patient-oriented research and mentoring.
Using pharmacoepidemiology to optimize antihypertensive medication use to prevent aging-related multimorbidity: Midcareer investigator award in patient-oriented research and mentoring.
批准号:
10572274
负责人:
Adam P Bress
金额:
$19.82万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-02-01 至 2028-01-31
关键词:
AccountabilityAgeAgingAlzheimer&aposs disease related dementiaAlzheimer&aposs disease riskAngiotensin II ReceptorAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsAreaAwardBiometryBlood PressureBrainCardiovascular DiseasesCareer ChoiceCognitiveColorCommunitiesCompetenceDataDedicationsDevelopment PlansDiabetes MellitusEducational CurriculumEducational workshopEnsureEnvironmentEvaluationFundingFutureGeriatricsGoalsHappinessHealth InsuranceHealth PersonnelHypertensionIndividualInfrastructureInstitutionInterventionIntervention TrialInvestmentsKnowledgeLearningLesionManuscriptsMentorsMentorshipMidcareer Investigator Award in Patient-Oriented ResearchMorbidity - disease rateNeeds AssessmentOutcomePatientsPersonsPharmaceutical PreparationsPharmacoepidemiologyPharmacy facilityPopulationPositioning AttributePrevalencePrincipal InvestigatorProcessProductivityPublic HealthReasons for Geographic And Racial Differences in StrokeRegimenResearchResearch PersonnelResearch Project GrantsResourcesRisk FactorsRisk ReductionRoleScientistServicesStructureTechniquesTestingTimeTrainingTraining ProgramsUnderrepresented PopulationsUniversitiesUpdateUtahWomanWorkWritingblood pressure controlblood pressure elevationblood pressure interventioncardiovascular disorder preventioncardiovascular risk factorcareercareer developmentcognitive functiondesignexperiencefrailtyhealth equityimprovedmodifiable riskmortalitymultiple chronic conditionsnext generationpatient orientedpatient oriented researchpeer coachingpersonalized approachpopulation healthpreventprogramsskill acquisitionskillssocial health determinantssuccesssynergismtraining opportunitywhite matter
中文摘要
这项K24提案将使主要研究者Adam Bress博士有时间和支持(1)继续他的研究。
早期研究人员成功指导的跟踪记录,以及(2)扩大他的指导与年龄相关的
和面向患者的研究(POR)计划,以新的重点领域,包括健康的社会决定因素
(SDoH),因为它们与抗高血压(抗HTN)药物的使用、使用不足和不安全使用有关,
预防与衰老相关的多种疾病,包括阿尔茨海默病和相关痴呆症(ADRD),
心血管疾病(CVD)。他的短期职业目标是(1)加强他的指导技能,
对不同的受训人员进行文化敏感的指导,(2)学习分析SDOH的新技能
和认知,大脑结构和脆弱的结果,(3)扩大抗HTN的基础设施
犹他州大学(UU)的药物流行病学培训。指导计划:他的核心组成部分
辅导计划是一种个性化的培训方法,包括需求评估,个人
发展计划、同侪指导和编写问责制小组、持续的密集评价进程,
和广阔的导师网络。研究战略与职业目标的协同作用,
指导计划:安全有效的抗HTN药物可预防发病率和死亡率,但通常
未充分利用或滥用。利用通过K24获得的新知识,Bress博士利用他成功的
POR计划,当前的资金和强大的机构资源,以创造独特的培训机会
通过三个明确定义的,相关的,和学员领导的关于老龄化的POR项目。这些研究利用了
使用收缩压(BP)干预试验(SPRINT)的现有R 01资助的POR,控制措施
糖尿病心血管风险(雅阁)研究,以及地理和种族差异的原因
卒中(REGARDS)研究。本研究的目的是:(1)确定密集的人群健康影响
根据SDoH和虚弱状态使用REGARDS进行血压(BP)治疗,(2)确定
REGARDS中药房沙漠、抗HTN药物使用和BP控制之间的关联,以及(3)
确定血管紧张素II受体阻滞剂与血管紧张素转换酶抑制剂的相关性,
SPRINT和雅阁的认知功能和白色病变体积。通过这些研究,学员
获得以下方面的实践经验:(1)在与其职业生涯相匹配的领域开展和领导与老龄化相关的POR
目标,(2)手稿撰写和传播,以及(3)获得初步数据以支持自己的K/R 01
应用.总结:Bress博士在与衰老相关的HTN药物流行病学方面对POR的坚定承诺,
个性化的指导计划,学员的直接参与,专家共同导师的可用性,以及
出色的机构支持是确保他的学员具有强大的POR生产力的优势
并获得成为独立科学家所需的技能和经验,
开展、评估和传播高质量的老龄化相关POR。
英文摘要
This K24 proposal will allow the principal investigator, Dr. Adam Bress, time and support to (1) continue his
track record of successful mentorship of early-stage investigators and (2) expand his mentored aging-related
and patient-oriented research (POR) program to new focus areas, including social determinants of health
(SDoH) as they relate to the use, underuse, and unsafe use of antihypertensive (anti-HTN) medications to
prevent aging-related multimorbidity including Alzheimer’s disease and related dementias (ADRD) and
cardiovascular disease (CVD). His short-term career goals are to (1) strengthen his mentoring skills in
culturally-sensitive mentoring across a diverse cadre of trainees, (2) learn new skills in the analysis of SDoH
and cognitive, brain structure, and frailty outcomes, and (3) expand infrastructure for anti-HTN
pharmacoepidemiology training at the University of Utah (UU). Mentoring Plan: A central component of his
mentoring program is an individualized approach to training, which includes a needs assessment, individual
development plan, peer-mentoring and writing accountability groups, ongoing intensive evaluation process,
and expansive mentorship network. Research Strategy and Synergy with Career Objectives and
Mentoring Plan: Safe and effective anti-HTN medications prevent morbidity and mortality but are often
underused or misused. Using new knowledge gained through the K24, Dr. Bress leverages his successful
POR program, current funding, and robust institutional resources to create unique training opportunities
through three well-defined, related, and mentee-led POR projects on aging. These studies leverage
existing R01-funded POR using the Systolic Blood Pressure (BP) Intervention Trial (SPRINT), Action to Control
Cardiovascular Risk in Diabetes (ACCORD) study, and REasons for Geographic And Racial Differences in
Stroke (REGARDS) study. The research aims are to (1) determine the population health impact of intensive
blood pressure (BP) treatment according to SDoH and frailty status using REGARDS, (2) determine
associations among pharmacy deserts, anti-HTN medication use, and BP control in REGARDS, and (3)
determine the association of angiotensin II receptor blocker vs. angiotensin-converting enzyme inhibitor use on
cognitive function and white matter lesion volume in SPRINT and ACCORD. Through these studies, mentees
gain practical experience in (1) conducting and leading aging-related POR in an area that matches their career
goals, (2) manuscript writing and dissemination, and (3) obtaining preliminary data to support their own K/R01
applications. Summary: Dr. Bress's strong commitment to POR in aging-related HTN pharmacoepidemiology,
an individualized mentorship plan, direct involvement of the mentees, availability of expert co-mentors, and
outstanding institutional support are strengths that will ensure that his mentees have strong POR productivity
and gain the skills and experience necessary to become independent scientists with competencies in
conducting, evaluating, and disseminating high-quality aging-related POR.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Informing optimal first-line antihypertensive therapy: A rigorous comparative effectiveness analysis of ARBs vs. ACEIs on long-term risk of dementia, cancer, heart disease, and quality of life
-
批准号:10340245
-
项目类别:
-
资助金额:$80.87万
-
财政年份:2022
-
负责人:Adam P Bress
-
依托单位:
Informing optimal first-line antihypertensive therapy: A rigorous comparative effectiveness analysis of ARBs vs. ACEIs on long-term risk of dementia, cancer, heart disease, and quality of life
-
批准号:10592258
-
项目类别:
-
资助金额:$77.41万
-
财政年份:2022
-
负责人:Adam P Bress
-
依托单位:
Guiding next steps for SPRINT-MIND implementation: Identifying high-benefit subgroups and comparative effects of ARB- vs. ACEI-based regimens
-
批准号:10392453
-
项目类别:
-
资助金额:$67.38万
-
财政年份:2020
-
负责人:Adam P Bress
-
依托单位:
Guiding next steps for SPRINT-MIND implementation: Identifying high-benefit subgroups and comparative effects of ARB- vs. ACEI-based regimens
-
批准号:10052751
-
项目类别:
-
资助金额:$69.87万
-
财政年份:2020
-
负责人:Adam P Bress
-
依托单位:
Guiding next steps for SPRINT-MIND implementation: Identifying high-benefit subgroups and comparative effects of ARB- vs. ACEI-based regimens
-
批准号:10614396
-
项目类别:
-
资助金额:$67.1万
-
财政年份:2020
-
负责人:Adam P Bress
-
依托单位:
Guiding next steps for SPRINT-MIND implementation: Identifying high-benefit subgroups and comparative effects of ARB- vs. ACEI-based regimens
-
批准号:10225636
-
项目类别:
-
资助金额:$67.17万
-
财政年份:2020
-
负责人:Adam P Bress
-
依托单位:
Patient Level Prediction of Clinical Outcomes and Cost-Effectiveness in SPRINT (Optimize-SPRINT)
-
批准号:10083758
-
项目类别:
-
资助金额:$76.27万
-
财政年份:2017
-
负责人:Adam P Bress
-
依托单位:
Genetic ancestry and antihypertensive medication responses in African Americans
-
批准号:9162980
-
项目类别:
-
资助金额:$16.55万
-
财政年份:2016
-
负责人:Adam P Bress
-
依托单位:
Genetic ancestry and antihypertensive medication responses in African Americans
-
批准号:9352867
-
项目类别:
-
资助金额:$16.55万
-
财政年份:2016
-
负责人:Adam P Bress
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: